Regulation of T cell immunity and tolerance in vivo by CD4

Xiaoli Shen, Rolf König

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Previous experiments showed that peptides corresponding to a major CD4-binding site on the β2 domain of MHC class II molecules, IAβ134-148, enhance responses by CD4+ T lymphocytes to antigen, allo-antigen and bacterial superantigen in vitro, and to soluble protein in vivo. To determine whether peptide IAβ134-148 acted by inhibiting antigen-induced T cell tolerance, ovalbumin-specific CD4+ lymph node (LN) T cells from TCR transgenic DO.11.10 mice were adoptively transferred into H-2 syngeneic BALB/c recipients. Tolerance was then induced by injecting antigen i.v. When peptide IAβ134-148 was used to interfere with CD4-MHC class II interactions, accumulation of clonotype-positive T lymphocytes in the LN and induction of T cell tolerance in vivo were delayed. The mechanism by which peptide IAβ134-148 inhibited T cell tolerance included the peptide's ability to block activation-induced cell death. Further, antigen-specific splenic T lymphocytes were not tolerized in IAβ134-148-treated mice, providing a reservoir of T cells that could respond to a secondary immunization. The results reported here suggest that participation of the T cell co-receptor, CD4, in TCR signaling differentially affected both T cell migration and the induction of antigen-specific tolerance. Therefore, in this in vivo model system, the combined strength of all signals received (e.g. via TCR, co-receptors and co-stimulators) determined whether T cell immunity or apoptosis and tolerance resulted from antigenic stimulation. These findings are potentially important for the development of reagents to enhance vaccine efficacy and tumor immunity.

Original languageEnglish (US)
Pages (from-to)247-257
Number of pages11
JournalInternational Immunology
Volume10
Issue number3
DOIs
StatePublished - 1998

Fingerprint

Immunity
T-Lymphocytes
Antigens
Peptides
Lymph Nodes
Bacterial Antigens
Secondary Immunization
Superantigens
Cancer Vaccines
Ovalbumin
T-Cell Antigen Receptor
Cell Movement
Cell Death
Binding Sites
Apoptosis

ASJC Scopus subject areas

  • Immunology

Cite this

Regulation of T cell immunity and tolerance in vivo by CD4. / Shen, Xiaoli; König, Rolf.

In: International Immunology, Vol. 10, No. 3, 1998, p. 247-257.

Research output: Contribution to journalArticle

Shen, Xiaoli ; König, Rolf. / Regulation of T cell immunity and tolerance in vivo by CD4. In: International Immunology. 1998 ; Vol. 10, No. 3. pp. 247-257.
@article{f136f02c0d9e49218bbb63358674f5eb,
title = "Regulation of T cell immunity and tolerance in vivo by CD4",
abstract = "Previous experiments showed that peptides corresponding to a major CD4-binding site on the β2 domain of MHC class II molecules, IAβ134-148, enhance responses by CD4+ T lymphocytes to antigen, allo-antigen and bacterial superantigen in vitro, and to soluble protein in vivo. To determine whether peptide IAβ134-148 acted by inhibiting antigen-induced T cell tolerance, ovalbumin-specific CD4+ lymph node (LN) T cells from TCR transgenic DO.11.10 mice were adoptively transferred into H-2 syngeneic BALB/c recipients. Tolerance was then induced by injecting antigen i.v. When peptide IAβ134-148 was used to interfere with CD4-MHC class II interactions, accumulation of clonotype-positive T lymphocytes in the LN and induction of T cell tolerance in vivo were delayed. The mechanism by which peptide IAβ134-148 inhibited T cell tolerance included the peptide's ability to block activation-induced cell death. Further, antigen-specific splenic T lymphocytes were not tolerized in IAβ134-148-treated mice, providing a reservoir of T cells that could respond to a secondary immunization. The results reported here suggest that participation of the T cell co-receptor, CD4, in TCR signaling differentially affected both T cell migration and the induction of antigen-specific tolerance. Therefore, in this in vivo model system, the combined strength of all signals received (e.g. via TCR, co-receptors and co-stimulators) determined whether T cell immunity or apoptosis and tolerance resulted from antigenic stimulation. These findings are potentially important for the development of reagents to enhance vaccine efficacy and tumor immunity.",
author = "Xiaoli Shen and Rolf K{\"o}nig",
year = "1998",
doi = "10.1093/intimm/10.3.247",
language = "English (US)",
volume = "10",
pages = "247--257",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Regulation of T cell immunity and tolerance in vivo by CD4

AU - Shen, Xiaoli

AU - König, Rolf

PY - 1998

Y1 - 1998

N2 - Previous experiments showed that peptides corresponding to a major CD4-binding site on the β2 domain of MHC class II molecules, IAβ134-148, enhance responses by CD4+ T lymphocytes to antigen, allo-antigen and bacterial superantigen in vitro, and to soluble protein in vivo. To determine whether peptide IAβ134-148 acted by inhibiting antigen-induced T cell tolerance, ovalbumin-specific CD4+ lymph node (LN) T cells from TCR transgenic DO.11.10 mice were adoptively transferred into H-2 syngeneic BALB/c recipients. Tolerance was then induced by injecting antigen i.v. When peptide IAβ134-148 was used to interfere with CD4-MHC class II interactions, accumulation of clonotype-positive T lymphocytes in the LN and induction of T cell tolerance in vivo were delayed. The mechanism by which peptide IAβ134-148 inhibited T cell tolerance included the peptide's ability to block activation-induced cell death. Further, antigen-specific splenic T lymphocytes were not tolerized in IAβ134-148-treated mice, providing a reservoir of T cells that could respond to a secondary immunization. The results reported here suggest that participation of the T cell co-receptor, CD4, in TCR signaling differentially affected both T cell migration and the induction of antigen-specific tolerance. Therefore, in this in vivo model system, the combined strength of all signals received (e.g. via TCR, co-receptors and co-stimulators) determined whether T cell immunity or apoptosis and tolerance resulted from antigenic stimulation. These findings are potentially important for the development of reagents to enhance vaccine efficacy and tumor immunity.

AB - Previous experiments showed that peptides corresponding to a major CD4-binding site on the β2 domain of MHC class II molecules, IAβ134-148, enhance responses by CD4+ T lymphocytes to antigen, allo-antigen and bacterial superantigen in vitro, and to soluble protein in vivo. To determine whether peptide IAβ134-148 acted by inhibiting antigen-induced T cell tolerance, ovalbumin-specific CD4+ lymph node (LN) T cells from TCR transgenic DO.11.10 mice were adoptively transferred into H-2 syngeneic BALB/c recipients. Tolerance was then induced by injecting antigen i.v. When peptide IAβ134-148 was used to interfere with CD4-MHC class II interactions, accumulation of clonotype-positive T lymphocytes in the LN and induction of T cell tolerance in vivo were delayed. The mechanism by which peptide IAβ134-148 inhibited T cell tolerance included the peptide's ability to block activation-induced cell death. Further, antigen-specific splenic T lymphocytes were not tolerized in IAβ134-148-treated mice, providing a reservoir of T cells that could respond to a secondary immunization. The results reported here suggest that participation of the T cell co-receptor, CD4, in TCR signaling differentially affected both T cell migration and the induction of antigen-specific tolerance. Therefore, in this in vivo model system, the combined strength of all signals received (e.g. via TCR, co-receptors and co-stimulators) determined whether T cell immunity or apoptosis and tolerance resulted from antigenic stimulation. These findings are potentially important for the development of reagents to enhance vaccine efficacy and tumor immunity.

UR - http://www.scopus.com/inward/record.url?scp=0031889303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031889303&partnerID=8YFLogxK

U2 - 10.1093/intimm/10.3.247

DO - 10.1093/intimm/10.3.247

M3 - Article

C2 - 9576612

AN - SCOPUS:0031889303

VL - 10

SP - 247

EP - 257

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 3

ER -